Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.32 |
| ▸ | BRD9 | Q9H8M2 | 3/20 | 0.32 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.32 |
| ▸ | BPTF | Q12830 | 1/20 | 0.32 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.32 |
| ▸ | VNN1 | O95497 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbamic Acid SCHEMBL3119184 | 1.00 | BRD4 (0.32) | BRD4BRD9KAT2BBPTFLPAR1 | |
| SCHEMBL4199230 | 0.93 | BRD9 (0.36) | BRD4BRD9KAT2BBPTFLPAR1 | |
| SCHEMBL6065837 | 0.84 | LPAR1 (0.37) | BRD4BRD9KAT2BBPTFLPAR1 | |
| SCHEMBL6065834 | 0.80 | LPAR1 (0.36) | BRD4BRD9KAT2BBPTFLPAR1 | |
| SCHEMBL3119092 | 0.80 | LPAR1 (0.38) | BRD4BRD9KAT2BBPTFLPAR1 | |
| SCHEMBL6425412 | 0.79 | ALDH1A1 (0.37) | BRD4BRD9KAT2BBPTFLPAR1 | |
| Carbamic Acid SCHEMBL5499998 | 0.78 | CA1 (0.40) | BRD4BRD9LPAR1MAPTKDM4E | |
| SCHEMBL5500962 | 0.78 | ADRA2C (0.39) | BRD4BRD9KAT2BBPTFLPAR1 | |
| SCHEMBL4204205 | 0.77 | ALDH1A1 (0.41) | LPAR1VNN1MAPTKMT2AKDM4C | |
| SCHEMBL4199889 | 0.77 | GAA (0.32) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663245-B1 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2010-04-07 | — | — | EP | disclosed |
| US-7192943-B2 | Cephem compounds | ASTELLAS PHARMA INC. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-20050096306-A1 | Cephem compounds | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096306-A1 | Cephem compounds | CEP170, ASS1, C1S | BRD4 3465/4885BRD9 2353/4885KAT2B 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.